Deutsche Bank Upgrades McKesson Stock Price Outlook

In a recent update to its investment research report, Deutsche Bank has upgraded the stock price target for McKesson Corporation (MCK), a leading healthcare services company. The bank’s analysts now expect MCK shares to reach $65 per share in the next 12 months, up from their previous target of $60. The upgrade comes as McKesson prepares to spin off its pharmacy benefits management (PBM) business, a move that is expected to simplify the company’s operations and improve its focus on core healthcare services. Deutsche Bank’s analysts believe that the planned spin-off will help MCK refocus on its core strengths in hospital and specialty pharmacy, while also creating a more efficient and competitive PBM entity. The upgraded target price reflects Deutsche Bank’s confidence in McKesson’s ability to execute on its strategic plan and drive growth through a combination of cost savings and revenue enhancements. The bank’s analysts point to MCK’s strong track record of innovation and its commitment to investing in emerging technologies as key drivers of future growth. While the spin-off has created some uncertainty around McKesson’s financials, Deutsche Bank remains bullish on the company’s prospects. “We believe that McKesson is well-positioned for long-term success, driven by its strong brand portfolio, diversified revenue streams, and commitment to innovation,” said [analyst name] at Deutsche Bank. MCK shares have already responded positively to the upgraded target price, rising by several percent in trading following the news release.